Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma

John A. Lust, Martha Lacy, Steven R. Zeldenrust, Thomas Elmer Witzig, Laurie L. Moon-Tasson, Charles A. Dinarello, Kathleen A. Donovan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We report the long-term follow-up results of a phase II trial of IL-1 receptor antagonist and low-dose dexamethasone for early stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent multiple myeloma (IMM) without the need for immediate therapy. Forty seven patients were enrolled and subsequently treated with IL-1Ra; in 25/47 low-dose dexamethasone (20 mg weekly) was added. The primary endpoint was progression-free survival (PFS). In the clinical trial, three patients achieved a minor response (MR) to IL-1Ra alone; five patients a partial response (PR) and four patients an MR after addition of dexamethasone. Seven patients showed a decrease in the plasma cell labeling index (PCLI) which paralleled a decrease in the high sensitivity C-reactive protein (hs-CRP). The median PFS for the 47 patients was 1116 days (37.2 months). The median PFS for patients without (n=22) and with (n=25) a decrease in their baseline hs-CRP was 326 days (11 months) vs. 3139 days (104 months) respectively (P

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StateAccepted/In press - 2016

Fingerprint

Multiple Myeloma
Interleukin-1
C-Reactive Protein
Interleukin-6
Survival
Dexamethasone
Interleukin 1 Receptor Antagonist Protein
Disease-Free Survival
Interleukin-1 Receptors
Plasma Cells
Clinical Trials

ASJC Scopus subject areas

  • Hematology

Cite this

Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. / Lust, John A.; Lacy, Martha; Zeldenrust, Steven R.; Witzig, Thomas Elmer; Moon-Tasson, Laurie L.; Dinarello, Charles A.; Donovan, Kathleen A.

In: American Journal of Hematology, 2016.

Research output: Contribution to journalArticle

@article{4f23865c231947bb90deb49ff4f31661,
title = "Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma",
abstract = "We report the long-term follow-up results of a phase II trial of IL-1 receptor antagonist and low-dose dexamethasone for early stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent multiple myeloma (IMM) without the need for immediate therapy. Forty seven patients were enrolled and subsequently treated with IL-1Ra; in 25/47 low-dose dexamethasone (20 mg weekly) was added. The primary endpoint was progression-free survival (PFS). In the clinical trial, three patients achieved a minor response (MR) to IL-1Ra alone; five patients a partial response (PR) and four patients an MR after addition of dexamethasone. Seven patients showed a decrease in the plasma cell labeling index (PCLI) which paralleled a decrease in the high sensitivity C-reactive protein (hs-CRP). The median PFS for the 47 patients was 1116 days (37.2 months). The median PFS for patients without (n=22) and with (n=25) a decrease in their baseline hs-CRP was 326 days (11 months) vs. 3139 days (104 months) respectively (P",
author = "Lust, {John A.} and Martha Lacy and Zeldenrust, {Steven R.} and Witzig, {Thomas Elmer} and Moon-Tasson, {Laurie L.} and Dinarello, {Charles A.} and Donovan, {Kathleen A.}",
year = "2016",
doi = "10.1002/ajh.24352",
language = "English (US)",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma

AU - Lust, John A.

AU - Lacy, Martha

AU - Zeldenrust, Steven R.

AU - Witzig, Thomas Elmer

AU - Moon-Tasson, Laurie L.

AU - Dinarello, Charles A.

AU - Donovan, Kathleen A.

PY - 2016

Y1 - 2016

N2 - We report the long-term follow-up results of a phase II trial of IL-1 receptor antagonist and low-dose dexamethasone for early stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent multiple myeloma (IMM) without the need for immediate therapy. Forty seven patients were enrolled and subsequently treated with IL-1Ra; in 25/47 low-dose dexamethasone (20 mg weekly) was added. The primary endpoint was progression-free survival (PFS). In the clinical trial, three patients achieved a minor response (MR) to IL-1Ra alone; five patients a partial response (PR) and four patients an MR after addition of dexamethasone. Seven patients showed a decrease in the plasma cell labeling index (PCLI) which paralleled a decrease in the high sensitivity C-reactive protein (hs-CRP). The median PFS for the 47 patients was 1116 days (37.2 months). The median PFS for patients without (n=22) and with (n=25) a decrease in their baseline hs-CRP was 326 days (11 months) vs. 3139 days (104 months) respectively (P

AB - We report the long-term follow-up results of a phase II trial of IL-1 receptor antagonist and low-dose dexamethasone for early stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent multiple myeloma (IMM) without the need for immediate therapy. Forty seven patients were enrolled and subsequently treated with IL-1Ra; in 25/47 low-dose dexamethasone (20 mg weekly) was added. The primary endpoint was progression-free survival (PFS). In the clinical trial, three patients achieved a minor response (MR) to IL-1Ra alone; five patients a partial response (PR) and four patients an MR after addition of dexamethasone. Seven patients showed a decrease in the plasma cell labeling index (PCLI) which paralleled a decrease in the high sensitivity C-reactive protein (hs-CRP). The median PFS for the 47 patients was 1116 days (37.2 months). The median PFS for patients without (n=22) and with (n=25) a decrease in their baseline hs-CRP was 326 days (11 months) vs. 3139 days (104 months) respectively (P

UR - http://www.scopus.com/inward/record.url?scp=84963893691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963893691&partnerID=8YFLogxK

U2 - 10.1002/ajh.24352

DO - 10.1002/ajh.24352

M3 - Article

C2 - 26945843

AN - SCOPUS:84963893691

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

ER -